Transcutaneous immunization: T cell responses and boosting of existing immunity

Vaccine

Volumn 19, Issue 17-19, 2001, Pages 2701-2707

  Hammond, Scott A ^a,b   Walwender, Deborah ^a,b   Alving, Carl R ^a   Glenn, Gregory M ^a,b  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b IOMAI Corporation   (United States)

Author keywords

Tetanus toxoid; Transcutaneous immunization; Vaccine

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; ANTIBODY; ANTIGEN; CHOLERA TOXIN; ENTEROTOXIN; LTR 192G; PURIFIED CHOLERA TOXIN B; RECOMBINANT CHOLERA TOXIN B; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; CELLULAR IMMUNITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; HYDRATION; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOLOGICAL MEMORY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SKIN; T LYMPHOCYTE; VACCINE PRODUCTION; VALIDATION PROCESS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; CHOLERA TOXIN; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; IMMUNIZATION; IMMUNIZATION, SECONDARY; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES; TETANUS TOXOID; TH1 CELLS; TH2 CELLS; VACCINES;

EID: 0035925699     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00506-5     Document Type: Conference Paper

References (31)

1. Skin immunization made possible by cholera toxin
2. Transcutaneous immunization induces systemic and mucosal immunity: A potent method for targeting immunity to the female reporductive tract
3. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants
4. Cutaneous vaccination: The skin as an immunologically active tissue and the challenge of antigen delivery
5. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants
6. Transcutaneous immunization of domestic animals: Opportunities and challenges
7. Vaccines and infectious disease
8. Vaccine developments
9. Epicutaneous and transcutaneous immunization using DNA or proteins
10. Advances in vaccine adjuvants
11. Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection
12. DNA-based immunization by in vivo transfection of dendritic cells
13. Immunization through dermal delivery of protein-encoding DNA: A role for migratory dendritic cells
14. Transdermal immunization with large proteins by means of ultradeformable drug carriers
15. Noninvasive administration of protein antigens: Transdermal immunization with bovine serum albumin in transfersomes
16. Cutting Edge: Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge
17. Principles of transcutaneous immunization using cholera toxin as an adjuvant
18. Advances in vaccine delivery: Transcutaneous immunisation
19. LT(R192G), a non-toxic mutant of the heat-labile enterotoxin of Escherichia coli, elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp
20. Helper T cell subsets for immunoglobulin A responses: Oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa-associated tissues
21. The in vitro production of cytokines by mucosal lymphocytes immunized by oral administration of keyhole limpet hemocyanin using cholera toxin as an adjuvant
22. The mechanism of cholera toxin adjuvanticity
23. Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming
24. Dermatologic formulations
25. Transcutaneous immunization: A human vaccine delivery strategy using a patch
26. Cadherins and Langerhans cell immunobiology
27. The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins
28. Taking the sting out of shots: Control of vaccination-associated pain and adverse reactions
29. Reducing the risk of unsafe injections in immunization programmes, the role of injection equipment
30. The fall-off in serum concentration of tetanus antitoxin after primary and booster vaccination
31. Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process